Concordia Healthcare Corp. T.CXR.R

Re re re re re this board was dead

[Evenstephen]

Yes I know what you are saying. But what an opportunity for a big player to buy up the debt and give the company some breathing room. This company still has a global footprint. They face challenges but the new CEO seems like he's doing the right things. They brought in a consultant from bcg. If they can turn it around over the next few years, then the debt would be revalued. They can renegotiate it. I know it's a long shot but whoever bought up the debt now would make a fortune on the yield as long as the company is in a position to pay it.

[TraderBen]

In the transcripts of the earnings call, it is made clear that the consultant can not be engaged until H2.  Why do you think that is?  Get your head out of the sand.  The balance sheet is so tied up with debt they have no alternatives left except Chapter 11 Restructuring.  The equity will nosedive to the penny stocks and get kicked out of the small cap index.  

[happyretirement]

"In the transcripts of the earnings call, it is made clear that the consultant can not be engaged until H2".  Possible misprint by SA???  HAS ALREADY with CC March 15th sounds like currently working.....JMO "We have brought on board an industry expert in the pharmaceutical sector, a 15-year former partner who specialized in pharmaceutical consulting at the Boston

[RodneyCameron]

How much is the bankruptcy advisors costing? Do they get paid before the bondholders?

[marcrobert]

There is no "bankruptcy" consultant. The guy is a pharma turnaround guy (business strategy). They can easily handling their debt oblgations in 2017, and then next biggie is 2021 at least thats what the ceo and cfo claim no imminent death.

[SpankedOnPaper]

Then why did they not give guidance? Concordia International Corp. 2017E Outlook Expected to Decline Although Formal Guidance Not Provided Management guided to single-digit price erosion relative to Q4/16 on a run-rate basis, which we believe leads to an Adj. EBITDA range of $313-341MM (3-9% decline). Combined with ongoing UK regulatory risk (NHS bill

[wheelingit]

They may be able to "handle" there interest payments and debt repayment in 2017, assuming the cashflow and EBITDA are accurate and in-line to the analysts "forecasts" which have zero guidance, however it leaves zero cashflow for anyone/anything else? Also it is a fair assumption that the depreciating cashflow and EBITDA seen in 2017 will pursure into 2018 with their existing